Large Skin Ulcer Due to a Subcutaneous Orthopaedic Implant After Bevacizumab Therapy: A Case Report

Case: Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is involved in the inhibition of vasculogenesis and angiogenesis. We report the case of a patient who developed a severe skin ulcer at the site of the surgical incision 5 years after clavicular fracture fixation with a titanium plate. This ulcer represents an adverse event of bevacizumab therapy for sigmoid colon cancer. Conclusion: Bevacizumab therapy is widely used, particularly for the treatment of metastatic colon cancer and other solid tumors, although it is associated with several adverse events, including delayed wound-healing and skin ulcers. However, to our knowledge, orthopaedic-related adverse events have not previously been reported.

[1]  M. Ara,et al.  Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. , 2014, Actas dermo-sifiliograficas.

[2]  M. Ara,et al.  Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. , 2014, Actas dermo-sifiliograficas.

[3]  P. Henry,et al.  Rate of and Risk Factors for Reoperations After Open Reduction and Internal Fixation of Midshaft Clavicle Fractures: A Population-Based Study in Ontario, Canada. , 2014, The Journal of bone and joint surgery. American volume.

[4]  A. Freedman,et al.  Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database , 2012, Drug Safety.

[5]  O. van der Meijden,et al.  Systematic review of the complications of plate fixation of clavicle fractures , 2012, Archives of Orthopaedic and Trauma Surgery.

[6]  P. Cottu,et al.  Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy , 2011, Anti-cancer drugs.

[7]  A. Vincent-Salomon,et al.  Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. , 2011, Journal of wound care.

[8]  J. Oh,et al.  Treatment of distal clavicle fracture: a systematic review of treatment modalities in 425 fractures , 2011, Archives of Orthopaedic and Trauma Surgery.

[9]  G. Giaccone,et al.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib , 2010, Journal of experimental & clinical cancer research : CR.

[10]  L. Ellis,et al.  Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. , 2010, The Lancet. Oncology.

[11]  K. Almhanna,et al.  Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. , 2008, Anti-cancer drugs.

[12]  S. Natsugoe,et al.  Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case , 2014, Surgery Today.